Elvitegravir
Back to searchMolecule Structure
Scientific Name
Elvitegravir
Description of the Drug
Elvitegravir is an antiretroviral agent used in combination with other antiretrovirals for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09101
http://www.drugbank.ca/drugs/DB09101
Brand Name(s)
Vitekta
Company Owner(s)
Gilead Sciences Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Human immunodeficiency virus type 1 integrase | SINGLE PROTEIN | INHIBITOR | CHEMBL3471 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL726252 |
| DrugBank | DB09101 |
| PubChem: Thomson Pharma | 16816905 |
| PubChem | 5277135 |
| LINCS | LSM-5647 |
| Nikkaji | J2.543.801I |
| PDBe | ELV |
| BindingDB | 50183273 |
| DrugCentral | 4300 |
| ChemicalBook | CB02464875 |
| rxnorm | ELVITEGRAVIR |
| PubChem: Drugs of the Future | 12015964 |
| ChEBI | 72289 |
| ZINC | ZINC000013682481 |
